Cargando…

Challenges and opportunities in real‐world evidence on the renal effects of sodium‐glucose cotransporter‐2 inhibitors

With increasing population aging and prevalence of type 2 diabetes (T2D) worldwide, prevention of diabetic complications remains a major unmet need. While cardiovascular outcomes of diabetes are improving over time, diabetic kidney disease (DKD) still leads to an exceedingly high rate of end‐stage k...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fadini, Gian Paolo, Del Prato, Stefano, Avogaro, Angelo, Solini, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298781/ https://www.ncbi.nlm.nih.gov/pubmed/34747123 http://dx.doi.org/10.1111/dom.14599

Ejemplares similares

Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
por: Avogaro, Angelo, et al.
Publicado: (2016)

Assessment of Glucose Lowering Medications’ Effectiveness for Cardiovascular Clinical Risk Management of Real-World Patients with Type 2 Diabetes: Targeted Maximum Likelihood Estimation under Model Misspecification and Missing Outcomes
por: Sciannameo, Veronica, et al.
Publicado: (2022)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors – Real-World Data
por: Gallwitz, Baptist
Publicado: (2018)

Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene
por: Yang, Jeff Yufeng, et al.
Publicado: (2020)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
por: Poudel, Resham Raj
Publicado: (2013)

It Is All in the Blood: The Multifaceted Contribution of Circulating Progenitor Cells in Diabetic Complications
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Amelioration of Glucose Control Mobilizes Circulating Pericyte Progenitor Cells in Type 2 Diabetic Patients with Microangiopathy
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

Observational research on sodium glucose co‐transporter‐2 inhibitors: A real breakthrough?
por: Raschi, Emanuel, et al.
Publicado: (2018)

Time-resolved trajectory of glucose lowering medications and cardiovascular outcomes in type 2 diabetes: a recurrent neural network analysis
por: Longato, Enrico, et al.
Publicado: (2022)

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Effectiveness of adding alarms to flash glucose monitoring in adults with type 1 diabetes under routine care
por: Boscari, Federico, et al.
Publicado: (2022)

Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibitors: a practical guide for the Dutch cardiologist based on real-world experience
por: Zwart, K., et al.
Publicado: (2021)

Do sodium–glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real‐world study
por: Zhao, Bin, et al.
Publicado: (2021)

Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Managing diabetes in diabetic patients with COVID: where do we start from?
por: Avogaro, Angelo, et al.
Publicado: (2021)

Insulin enhances renal glucose excretion: relation to insulin sensitivity and sodium-glucose cotransport
por: Ferrannini, Ele, et al.
Publicado: (2020)

Biochemical Efficacy of Sodium–Glucose Cotransporter 2 Inhibitors by Cardiovascular Risk Profile and Volume Status in a Real-World Diabetic Population
por: Gitto, Mauro, et al.
Publicado: (2022)

Sodium–Glucose Cotransporter-2 Inhibitors Could Help Delay Renal Impairment in Patients with Type 2 Diabetes: A Real-World Clinical Setting
por: Park, Gyunam, et al.
Publicado: (2022)

Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Response to Chia Siang Kow and colleagues
por: Avogaro, Angelo, et al.
Publicado: (2022)

Sodium–glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria
por: Delanaye, Pierre, et al.
Publicado: (2021)

Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy
por: Castoldi, Giovanna, et al.
Publicado: (2021)

Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
por: Kim, Nam Hoon, et al.
Publicado: (2022)

Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World)
por: Udell, Jacob A., et al.
Publicado: (2018)

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
por: Longato, Enrico, et al.
Publicado: (2020)

Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes
por: Sciannameo, V., et al.
Publicado: (2021)

Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study
por: Saijo, Yuto, et al.
Publicado: (2023)

Sodium–glucose cotransporter 2 inhibitors in type 1 diabetes: a missed opportunity for cardiovascular protection?
por: Snaith, Jennifer R, et al.
Publicado: (2022)

Renal threshold for glucose reabsorption predicts diabetes improvement by sodium‐glucose cotransporter 2 inhibitor therapy
por: Osaki, Aya, et al.
Publicado: (2016)

Effects of Sodium Glucose Cotransporter 2 Inhibitor on Renal Renin-Angiotensin-Aldsoterone System
por: Takeda, Yoshiyu, et al.
Publicado: (2021)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status
por: Nunoi, Kiyohide, et al.
Publicado: (2019)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4evqpeel9fp65kicm59k67g6v4